Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Operating Leases (2019 - 2026)

Anika Therapeutics has reported Operating Leases over the past 8 years, most recently at $23.8 million for Q1 2026.

  • Quarterly Operating Leases rose 0.98% to $23.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $23.8 million through Mar 2026, up 0.98% year-over-year, with the annual reading at $24.2 million for FY2025, 0.76% up from the prior year.
  • Operating Leases was $23.8 million for Q1 2026 at Anika Therapeutics, down from $24.2 million in the prior quarter.
  • Over five years, Operating Leases peaked at $29.7 million in Q2 2022 and troughed at $18.8 million in Q1 2022.
  • The 5-year median for Operating Leases is $25.8 million (2024), against an average of $25.6 million.
  • Year-over-year, Operating Leases surged 50.27% in 2023 and then decreased 10.56% in 2025.
  • A 5-year view of Operating Leases shows it stood at $28.8 million in 2022, then fell by 10.07% to $25.9 million in 2023, then fell by 7.34% to $24.0 million in 2024, then rose by 0.76% to $24.2 million in 2025, then decreased by 1.66% to $23.8 million in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Operating Leases are $23.8 million (Q1 2026), $24.2 million (Q4 2025), and $22.8 million (Q3 2025).